| Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection (NCT01249443) | AIDS Malignancy Consortium | 2013-11-01 |
| Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC (NCT01283178) | Virginia Commonwealth University | 2011-07-01 |
| Transoral Robotic Surgery in Treating Patients With Benign or Stage I-IV Head and Neck Cancer (NCT01254734) | City of Hope Medical Center | 2011-04-01 |
| Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer (NCT01316757) | Fox Chase Cancer Center | 2011-02-16 |
| Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck (NCT01192815) | Case Comprehensive Cancer Center | 2011-01-01 |
| Esophagoscopy in Evaluating Treatment in Patients With Stage I-IV Head and Neck Cancer Who Are Undergoing Radiation Therapy and/or Chemotherapy (NCT01164566) | Wake Forest University Health Sciences | 2010-12-01 |
| L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck Cancer (NCT01155609) | University of Washington | 2010-09-01 |
| Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck (NCT01044433) | Abramson Cancer Center at Penn Medicine | 2009-10-01 |
| Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer (NCT01637194) | Fox Chase Cancer Center | 2008-11-01 |
| Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck (NCT00906360) | National Cancer Institute (NCI) | 2008-07-01 |
| Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer (NCT00492089) | National Cancer Institute (NCI) | 2007-06-01 |
| Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer (NCT00397384) | National Cancer Institute (NCI) | 2007-01-01 |
| SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (NCT00095628) | National Cancer Institute (NCI) | 2005-01-01 |
| Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer (NCT00101348) | National Cancer Institute (NCI) | 2005-01-01 |
| Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors (NCT00089362) | National Cancer Institute (NCI) | 2004-07-01 |
| 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) (NCT00031681) | National Cancer Institute (NCI) | 2001-12-01 |
| Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction (NCT00030498) | National Cancer Institute (NCI) | 2001-12-01 |
| Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer (NCT00023959) | National Cancer Institute (NCI) | 2001-07-01 |